List view / Grid view
10 November 2014 | By Genmab A/S
Genmab A/S announced today that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. plans to start an additional Phase III study of daratumumab in frontline multiple myeloma...
10 November 2014 | By Almirall
Almirall, the global pharmaceutical company based in Barcelona, announced year to date 2014 results...
10 November 2014 | By KU Leuven
A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost...
10 November 2014 | By Bristol-Myers Squibb
Study results from investigational agents Opdivo (nivolumab), elotuzumab, and ulocuplumab, as well as Sprycel (dasatinib), will be highlighted...
7 November 2014 | By Sartorius
With its new BIOSTAT A, Sartorius Stedim Biotech presents a compact bioreactor | fermenter designed specifically as an entry-level model for fermentation and cell culture as well as for educational purposes...
7 November 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue...
7 November 2014 | By TxCell
TxCell SA announces that Damian Marron, CEO, TxCell, will present at the 2nd Annual EU Advanced Therapies Investor Day in London...
Response from the British Generic Manufacturers Association (BGMA) to a new report issued today by the Academy of Medical Royal Colleges...
7 November 2014 | By Invetech and Argos Therapeutics
Invetech and Argos Therapeutics to partner on automated production of personalized immunotherapies for cancer and infectious diseases...
Janssen Research & Development, LLC (Janssen) today announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO® (bedaquiline) in the STREAM Study. The STREAM study is an ongoing, multi-centre international randomized controlled trial to evaluate a standardized treatment regimen of anti-tuberculosis drugs for patients…
5 November 2014 | By Roche
Addressing Asia Pacific’s growing demand for diagnostics...
5 November 2014 | By Allied Minds
Allied Minds, an innovative U.S. science and technology development and commercialization company, announced that Donna See, former Director of Licensing and Strategic Initiatives at Columbia University’s technology transfer office, has joined as Vice President to lead the firm’s partnerships with U.S. research universities...
5 November 2014 | By Public Health England
Around half of the people living with hepatitis C infections don’t know it, according to a new publication out today from Public Health England (PHE), “Shooting Up: Infections among people who inject drugs in the United Kingdom 2013”...
5 November 2014 | By Micreos
Micreos, a Dutch biotech company, has developed Staphefekt™, a bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA)...
5 November 2014 | By TxCell
TxCell (FR0010127662 - TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today reports its revenues(1) as of September 30, 2014...
